Testosterone therapy for women with poor ovarian response undergoing IVF: a meta-analysis of randomized controlled trials.
Abortion, Spontaneous
/ drug therapy
Anti-Mullerian Hormone
Birth Rate
Female
Fertilization in Vitro
/ drug effects
Humans
Infertility, Female
/ drug therapy
Live Birth
Oocytes
/ drug effects
Ovulation Induction
/ methods
Pregnancy
Pregnancy Outcome
Pregnancy Rate
Randomized Controlled Trials as Topic
Testosterone
/ therapeutic use
Clinical pregnancy rate
IVF outcome
Live birth rate
Poor ovarian responders
Supplementation
Testosterone
Journal
Journal of assisted reproduction and genetics
ISSN: 1573-7330
Titre abrégé: J Assist Reprod Genet
Pays: Netherlands
ID NLM: 9206495
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
21
07
2018
accepted:
27
11
2018
pubmed:
6
1
2019
medline:
28
8
2019
entrez:
6
1
2019
Statut:
ppublish
Résumé
The aim of the present systematic review and meta-analysis was to summarize evidence on the effectiveness of testosterone supplementation for poor ovarian responders (POR) on IVF outcomes. The primary outcome was live birth rate (LBR); secondary outcomes were clinical pregnancy rate (CPR), miscarriage rate (MR), total and MII oocytes, and total embryos. This meta-analysis of randomized controlled trials (RCTs) evaluates the effects of testosterone administration before/during COS compared with a control group in patients defined as POR. The primary outcome was live birth rate (LBR); secondary outcomes were clinical pregnancy rate (CPR), miscarriage rate (MR), total and MII oocytes, and total embryos. Pooled results were expressed as risk ratio (RR) or mean differences (MD) with 95% confidence interval (95% CI). Sources of heterogeneity were investigated through sensitivity and subgroup analysis. All analyses were performed by using the random-effects model. Women receiving testosterone showed higher LBR (RR 2.29, 95% CI 1.31-4.01, p = 0.004), CPR (RR 2.32, 95% CI 1.47-3.64, p = 0.0003), total oocytes (MD = 1.28 [95% CI 0.83, 1.73], p < 0.00001), MII oocytes (MD = 0.96 [95% CI 0.28, 1.65], p = 0.006), and total embryos (MD = 1.17 [95% CI 0.67, 1.67], p < 0.00001) in comparison to controls, with no difference in MR (p = ns). Sensitivity and subgroup analysis did not provide statistical changes to the pooled results. Testosterone therapy seems promising to improve the success at IVF in POR patients. Further RCTs with rigorous methodology and inclusion criteria are still mandatory.
Identifiants
pubmed: 30610664
doi: 10.1007/s10815-018-1383-2
pii: 10.1007/s10815-018-1383-2
pmc: PMC6505000
doi:
Substances chimiques
Testosterone
3XMK78S47O
Anti-Mullerian Hormone
80497-65-0
Types de publication
Journal Article
Meta-Analysis
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
673-683Références
Biol Reprod. 1999 Aug;61(2):353-7
pubmed: 10411511
J Clin Endocrinol Metab. 1999 Aug;84(8):2951-6
pubmed: 10443703
Hum Reprod. 2000 Oct;15(10):2129-32
pubmed: 11006185
Endocrinology. 2001 Nov;142(11):4930-6
pubmed: 11606461
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Domest Anim Endocrinol. 2004 Jul;27(1):81-8
pubmed: 15158536
Fertil Steril. 2004 Jun;81(6):1713-4
pubmed: 15193506
Fertil Steril. 2005 Feb;83(2):302-8
pubmed: 15705366
J Clin Endocrinol Metab. 2005 Jul;90(7):3847-53
pubmed: 15827095
Hum Reprod. 2006 May;21(5):1204-11
pubmed: 16476678
Hum Reprod. 2006 Jul;21(7):1884-93
pubmed: 16517559
Biol Reprod. 2006 Dec;75(6):924-32
pubmed: 16943368
Histopathology. 1991 Nov;19(5):445-52
pubmed: 1757084
Fertil Steril. 2009 Mar;91(3):749-66
pubmed: 18639875
Hum Reprod. 2009 Feb;24(2):349-59
pubmed: 19054777
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Hum Reprod. 2010 Mar;25(3):690-6
pubmed: 20031956
Fertil Steril. 2011 Feb;95(2):679-83
pubmed: 20801436
Hum Reprod. 2011 Feb;26(2):414-22
pubmed: 21147822
Reprod Biomed Online. 2011 Jun;22(6):545-55
pubmed: 21493151
Hum Reprod Update. 2012 Mar-Apr;18(2):127-45
pubmed: 22307331
Reprod Biomed Online. 2012 Nov;25(5):450-9
pubmed: 22999555
Reprod Sci. 2014 May;21(5):632-9
pubmed: 24155065
Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3008-13
pubmed: 24516121
J Clin Endocrinol Metab. 1989 Jan;68(1):200-7
pubmed: 2491861
Exp Ther Med. 2014 Jul;8(1):187-194
pubmed: 24944620
ISRN Obstet Gynecol. 2014 Apr 10;2014:818010
pubmed: 25006485
J Endocrinol. 2014 Sep;222(3):R141-51
pubmed: 25037707
Biomed Res Int. 2014;2014:352098
pubmed: 25136579
Hum Reprod. 2015 Feb;30(2):315-22
pubmed: 25432927
Gynecol Endocrinol. 2015 Apr;31(4):253-7
pubmed: 25482873
Hum Reprod. 2015 Mar;30(3):664-74
pubmed: 25567619
Reprod Biol Endocrinol. 2015 Apr 10;13:28
pubmed: 25884482
Reprod Biomed Online. 2015 Jun;30(6):581-92
pubmed: 25892496
Dev Reprod. 2014 Sep;18(3):145-52
pubmed: 25949183
Mol Med Rep. 2015 Sep;12(3):4219-4229
pubmed: 26059981
Reprod Sci. 2016 Jan;23(1):61-8
pubmed: 26156851
Fertil Steril. 2016 Jan;105(1):100-5.e1-6
pubmed: 26496380
Cochrane Database Syst Rev. 2015 Nov 26;(11):CD009749
pubmed: 26608695
Hum Reprod Update. 2016 Apr;22(3):306-19
pubmed: 26843539
Hum Reprod. 2016 May;31(5):977-85
pubmed: 26956551
Reprod Sci. 2018 Jul;25(7):980-982
pubmed: 27489169
Gynecol Endocrinol. 2017 Dec;33(12):977-979
pubmed: 28562099
Hum Reprod Update. 2017 Sep 1;23(5):560-579
pubmed: 28903472
J Res Med Sci. 2018 Jan 29;23:3
pubmed: 29456560
Reprod Biol Endocrinol. 2018 Mar 9;16(1):20
pubmed: 29523204
Curr Opin Obstet Gynecol. 2018 Jun;30(3):155-162
pubmed: 29664789
Fertil Steril. 2018 Jun;109(6):993-999
pubmed: 29935660
Front Endocrinol (Lausanne). 2018 Jun 14;9:317
pubmed: 29963011
Fertil Steril. 1986 Feb;45(2):202-8
pubmed: 3949022
Hum Reprod. 1997 Jan;12(1):107-11
pubmed: 9043913
J Clin Endocrinol Metab. 1998 Jul;83(7):2479-85
pubmed: 9661631